Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.64 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.64 |
| ▸ | ITGB6 | P18564 | 8/20 | 0.56 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744149 | 1.00 | ITGAV (0.64) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20139573 | 0.95 | ITGAV (0.57) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL29744082 | 0.95 | ITGAV (0.57) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL29744177 | 0.86 | ITGB3 (0.68) | ITGAVITGB3ITGB5ITGB6 | |
| SCHEMBL20139849 | 0.86 | ITGB3 (0.68) | ITGAVITGB3ITGB5ITGB6 | |
| SCHEMBL29744134 | 0.85 | ITGAV (0.64) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20139569 | 0.85 | ITGAV (0.64) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20139365 | 0.85 | ITGAV (0.57) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL29744370 | 0.85 | ITGAV (0.57) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL29744080 | 0.84 | ITGAV (0.61) | ITGAVITGB3ITGB5ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | claimed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | claimed |
| EP-3538519-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | claimed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | claimed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | claimed |
| US-20250333379-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-12297168-B2 | Compounds useful for treating liver diseases | ABIONYX PHARMA SA (FR) | 2025-05-13 | — | — | US | disclosed |
| US-20240199575-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2024-06-20 | — | — | US | disclosed |
| CN-117500791-A | Compounds useful for treating liver diseases | 阿比奥尼克斯制药公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2023-09-07 | — | — | US | disclosed |
| US-11634387-B2 | Compounds useful for treating liver diseases | ABIONYX PHARMA SA (FR) | 2023-04-25 | — | — | US | disclosed |
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2023-01-12 | — | — | US | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021059023-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2021-04-01 | — | — | WO | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | ITGAV 1/4885ITGB3 3/4885ITGB5 4/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | ITGAV 1/4885ITGB3 3/4885ITGB5 4/4885 |
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | ITGAV 2084/4885ITGB3 2435/4885ITGB5 2536/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | ITGAV 3/4885ITGB3 1/4885ITGB5 5/4885 |
| US-20240199575-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | SLC10A1, FABP1, CPT1A | ITGAV 2084/4885ITGB3 2435/4885ITGB5 2536/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | ITGAV 1/4885ITGB3 3/4885ITGB5 4/4885 |
| US-11634387-B2 | Compounds useful for treating liver diseases | SLC10A1, FABP1, CPT1A | ITGAV 2084/4885ITGB3 2435/4885ITGB5 2536/4885 |
| US-20250333379-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | ITGAV 2084/4885ITGB3 2435/4885ITGB5 2536/4885 |
| US-12297168-B2 | Compounds useful for treating liver diseases | SLC10A1, FABP1, CPT1A | ITGAV 2084/4885ITGB3 2435/4885ITGB5 2536/4885 |
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | SLC10A1, CPT1A, CES1 | ITGAV 3443/4885ITGB3 2396/4885ITGB5 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.